Andrew Charles, MD: FDA Approves Drug QULIPTA for Chronic Migraine

Andrew Charles

"The Food and Drug Administration (FDA) has approved the migraine drug atogepant (QULIPTA) for use in the preventive treatment of chronic migraine.

The drug was approved last year for the use of episodic migraine and will now also be an option for those with chronic migraine.

“This is certainly good news for those impacted by chronic migraine. It is great to have another therapeutic option for those who are disabled by this disease,” Dr. Andrew Charles, a professor of neurology and director of the University of California Los Angeles Goldberg Migraine Program, told Healthline.

“Atogepant is already approved for the prevention of episodic migraine (migraine with less than 15 days of headache per month), and we have been using it with good success for patients in this category,” he said. “The approval for chronic migraine will allow us to prescribe it within FDA guidelines for those with more frequent headache days, a population in which preventive treatment is essential.”


Currently, there is no cure for migraine as the causes behind it are not fully understood.

Treatment options are focused either on relieving symptoms when they occur or preventing migraine from happening in the first place.

Charles argues that for people experiencing chronic migraine, a preventive treatment is crucial, and the approval of atogepant in chronic migraine could fill a need for non-injectable options."

Read more at Healthline.